Hosted on MSN9mon
MediWound stock climbs 9% on Phase 2 data for wound care treatmentMediWound said Santyl is currently the market leader in enzymatic debridement products for wound care, with annual US sales in excess of $360M. A Phase 3 study of EscharEx is expected to begin in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback